GLP Watchdog
FDA-Approved MedicationUpdated September 2026

Zepbound Guide

Zepbound is the brand-name formulation of tirzepatide 2.5–15mg specifically FDA-approved for chronic weight management, launched by Eli Lilly in late 2023. It is chemically identical to Mounjaro but approved specifically for obesity treatment, making it eligible for different insurance coverage pathways and savings programs.

Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more

By Ruth Calder · Enforcement Editor
Editorially reviewed (not clinically reviewed). Not medical advice · How we verify contentLast reviewed

At a Glance

Generic NameTirzepatide
Brand NamesZepbound
FDA StatusFDA-approved for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity (November 2023)[1]
Approval DateNovember 8, 2023[1]

How Zepbound Works

Zepbound works through tirzepatide's dual GIP/GLP-1 mechanism to reduce appetite through both central brain signals and peripheral metabolic effects. GLP-1 activation creates feelings of fullness and slows digestion; GIP activation may additionally enhance fat metabolism and energy expenditure. This twin-hormone approach produces more weight loss than any single-pathway agent.[2]

Dosing Schedule

Zepbound uses a gradual dose escalation to minimize side effects. Always follow your prescriber's guidance and the current FDA label[1].

Weeks 1–42.5mg/week
Weeks 5–85mg/week
Weeks 9–127.5mg/week
Weeks 13–1610mg/week
Weeks 17–2012.5mg/week
Week 21+15mg/week (maintenance)

Side Effects

Common: nausea (31%), diarrhea (23%), vomiting (13%), constipation (12%), abdominal pain (9%), injection site redness. Nausea is most common during dose escalation and typically resolves within a month of each new dose. Serious (rare): pancreatitis, cholelithiasis (gallstones), thyroid tumor risk noted in animal models. The suicidal behavior and ideation section was removed from the label in February 2026.[1][2]

Nothing above is the full list. Your prescriber can give you the complete safety picture, and every adverse reaction on record sits in the current FDA prescribing information[1].

Clinical Trial Results

In the SURMOUNT-1 trial, Zepbound (tirzepatide 15mg) produced an average weight loss of 22.5% (about 52 lbs) over 72 weeks — the highest of any anti-obesity medication ever studied. The lower doses ran 21.4% at 10mg and 15.0% at 5mg. Against the 5%-of-body-weight bar, the 15mg dose put 91% of participants over it.[2][3]

Source: Published clinical trial data (STEP / SURMOUNT trial series) — see the Sources panel below for full citations.

Where to Get Zepbound

Sellers in our register that will dispense tirzepatide, or a compounded version of it, after an online consultation — shipped to your door.

7.4/ 10
Verified partner

MEDGm

Best for: month-to-month compounded semaglutide at $179 with the partner pharmacies named

★★★★☆3.7/5

Editorial score · methodology

$179/mo
CompoundedSemaglutideTirzepatide
Get StartedRead full MEDGm review →
6.7/ 10
Verified partner

RxSpan MD

Best for: knowing which pharmacy fills the vial: it names Belmar Pharmacy

★★★☆☆3.4/5

Editorial score · methodology

$179/mo
CompoundedSemaglutideTirzepatideGlutathioneNAD+LegitScript Verified
Get StartedRead full RxSpan MD review →
6.6/ 10
Verified partner

Luvo Health

Best for: moving between compounded and brand without changing seller

★★★☆☆3.3/5

Editorial score · methodology

$249/mo
CompoundedSemaglutideTirzepatideGonadorelinNAD+LegitScript Verified
Get StartedRead full Luvo Health review →
6.1/ 10
Verified partner

DudeMeds

Best for: compounded semaglutide at $175/month

★★★☆☆3.1/5

Editorial score · methodology

$175/mo
CompoundedSemaglutideTirzepatideNAD+
Get StartedRead full DudeMeds review →
8.9/ 10

Aspire Health

Best for: a published price you can check dose by dose before handing over any health information

★★★★★4.5/5

Editorial score · methodology

$103/mo
CompoundedSemaglutideTirzepatide
Get StartedRead full Aspire Health review →
8.8/ 10

AskRx

Best for: coverage in all 50 states, which most sellers will not confirm

★★★★☆4.4/5

Editorial score · methodology

$199/mo
BrandSemaglutideTirzepatide
Get StartedRead full AskRx review →

Cost Comparison

Zepbound cost & pricing →Savings & coupons →Side effects →Dosing & titration →How to get it →Storage & handling →Alternatives →Manufacturer coupon →

What each seller in the register charges to start on a compounded GLP-1, cheapest at the top. Compounded tirzepatide from licensed 503A and 503B pharmacies is legal under federal compounding law[4], and the rules have historically loosened further for any molecule sitting on the FDA Drug Shortage List[5]. An FSA or HSA will generally cover either kind of prescription, compounded or branded, under IRS Publication 502[6]. What you actually pay moves with your dose and with whatever promotion happens to be running.

ProviderStarting PriceLink
The Virtual NP$75/moVisit
Kin Meds$149/moVisit
AskRx$299/moVisit
Aspire Health$299/moVisit
GoodRx$299/moVisit
Klinic$299/moVisit
PreventiveMD$299/moVisit
Knownwell$349/moVisit
Noom$349/moVisit
Rex MD$349/moVisit
Show all 21 Zepbound sellers
Zepbound sellers 11 to 21, cheapest first
RxSpan MD$1,069/moVisit
Vaylen$1,086/moVisit
altRX$1,249/moVisit
Effecty$1,300/moVisit
DudeMeds$1,350/moVisit
HeliMeds$1,396/moVisit
Aquivia Health$1,399/moVisit
Luvo Health$1,399/moVisit
BiltRx$1,499/moVisit
Fridays$1,828/moVisit
NuuVim$1,892/moVisit

Zepbound Head-to-Head Comparisons

Short verdict pages setting Zepbound against the other GLP-1 options, working from the trial results, the dose ladders on each label, and what the manufacturers charge today.

Zepbound vs Wegovy
A real head-to-head exists here, which is rare. SURMOUNT-5 put Zepbound at 20.2% against Wegovy at 13.7% over 72 weeks, matching what their separate trials had suggested.
Last verified 2026-05-27
Zepbound vs Mounjaro
One molecule from one manufacturer under two names. The label is the whole difference: diabetes on one side, obesity and sleep apnea on the other, at identical doses and identical cash prices.
Last verified 2026-05-27
Zepbound vs Ozempic
Different molecules, different labels, and a head-to-head that favors one clearly: 20.2% against 13.7% at 72 weeks in SURMOUNT-5.
Last verified 2026-05-27
Zepbound vs Foundayo
Both are approved for weight, which makes this a rare like-for-like comparison. The injection takes off about twice as much; the pill needs no needle and no food rules.
Last verified 2026-05-27
Zepbound vs Saxenda
Saxenda is a daily injection approved from age 12. Zepbound is a weekly injection, adults only, at roughly three times the weight loss and a third of the cash price.
Last verified 2026-05-28
Zepbound vs Rybelsus
Rybelsus is daily oral semaglutide, labeled for diabetes only, with a strict 30-minute fast. Zepbound is weekly tirzepatide, labeled for weight and sleep apnea. About 4% against about 21%.
Last verified 2026-05-28

See all drug-vs-drug verdicts.

Pivotal Zepbound Trial Walkthroughs

The trials that produced the Zepbound label, taken endpoint by endpoint, with the figures read off the source.

SURMOUNT-1
SURMOUNT-1 put tirzepatide at 5, 10 and 15 mg weekly against placebo in 2,539 adults who had obesity, or excess weight plus a related complication. The top dose reached -20.9% body weight at 72 weeks against -3.1% on placebo — more than any approved weight drug had achieved in a phase 3 trial, and the evidence behind Zepbound's approval. It also reset what the whole market claims it can deliver, including products carrying no trial evidence whatsoever.
3 · N=2,539 · Last verified 2026-05-27
SURMOUNT-OSA
SURMOUNT-OSA tested tirzepatide in 469 people carrying obesity alongside moderate-to-severe obstructive sleep apnea, split into two cohorts — those using positive airway pressure and those not. The apnea-hypopnea index fell 25.3 events an hour without PAP and 29.3 with it, against roughly 5 on placebo. It produced a second FDA indication for Zepbound and turned a weight-management drug into a treatment for a specific, diagnosable condition.
Phase 3 · N=469 · Last verified 2026-05-28
SURMOUNT-2
SURMOUNT-2 ran tirzepatide in the population SURMOUNT-1 excluded: adults with type 2 diabetes as well as obesity. At 15 mg the result was −14.7% body weight at 72 weeks against −3.2% on placebo. That is a substantial effect and it is six percentage points below what the same drug produced in people without diabetes, which is the single most useful comparison anyone with diabetes can make when reading marketing built on SURMOUNT-1.
3 · N=938 · Last verified 2026-05-28
SURMOUNT-3
SURMOUNT-3 answered a question the other trials skip: what does the drug add for someone who has already succeeded with lifestyle change? All 579 participants completed a 12-week intensive lifestyle lead-in first. Those randomized to tirzepatide then lost a further 18.4%; those on placebo regained 2.5%. The design isolates the drug's contribution on top of behavioral success rather than instead of it.
3 · N=579 · Last verified 2026-05-28

Zepbound Patient Questions, Answered

Questions people actually asked about Zepbound in named subreddits, each answered from the published trial data.

The 10 Tirzepatide Questions People Actually Ask, Answered From the Trials
10 questions · 11 PubMed citations
Last verified 2026-05-27
GLP-1 Coverage: the 10 Questions People Ask After a Denial
10 questions · 12 PubMed citations
Last verified 2026-05-28
Injecting a GLP-1: 10 Technique Questions, Answered
10 questions · 11 PubMed citations
Last verified 2026-05-28
GLP-1 Plateaus: 10 Questions About Why the Scale Stopped
10 questions · 10 PubMed citations
Last verified 2026-05-28

Zepbound Reference Cards

One-screen references for the dose schedule, what to do about a missed dose, and the side effects that warrant a call. Every figure checked against the DailyMed label.

Zepbound Dose Steps Cheat Sheet: the 96-Hour Rule
The Zepbound ladder is often described as six steps to 15 mg, which quietly implies 15 mg is where you are meant to end up. The label says something different: raise the dose in 2.5 mg increments until you reach a maintenance dose that works, and three doses qualify — 5, 10 and 15 mg. This page sets out the steps, the four-day window for a missed dose, the 72-hour rule for moving injection day, and the symptoms that mean stop climbing.
4 min read · Last verified 2026-05-27
GLP-1 Injection Sites: Rotation, Technique and the Lump to Avoid
Every weekly GLP-1 permits the same three injection sites and every one of them tells you to move around. The reason is a lump called lipohypertrophy — thickened fat that soaks up the drug at an unpredictable rate. When absorption becomes erratic so does appetite suppression, and a stalled month gets blamed on the dose when the cause is a favorite square inch of belly.
4 min read · Last verified 2026-05-28
Switching Between GLP-1s: Why You Start at the Bottom Again
Switching is common — a formulary changes, side effects bite, or you reach the top of a ladder with weight still to lose — and no label tells you how to do it. The rule that surprises people is that you go back to the bottom even though you have been on a GLP-1 for a year. Tolerating one of these drugs does not buy you tolerance of another, because they do not act on the same receptors.
5 min read · Last verified 2026-05-28

Ranked PubMed Studies on Zepbound

The peer-reviewed studies on Zepbound and its neighbours that carry the most weight, gathered into lists. Every PMID was checked against PubMed esummary rather than recalled.

The 10 Tirzepatide Trials That Built the Case (2026)
Tirzepatide is the only dual GIP and GLP-1 agonist with a finished phase 3 obesity program, and the ten trials below are why it currently sits at the top of the evidence. They cover the pivotal result, what happens in diabetes, what happens when you stop, the direct comparison against semaglutide, and two indications — sleep apnea and heart failure — that have nothing to do with the scale.
10 ranked papers · Last verified 2026-08-16
GLP-1s and Bone: 10 Studies on a Risk Nobody Has Measured Properly
Losing weight quickly costs bone density no matter how it is done. Whether these drugs add anything on top of that is unsettled — one randomized trial says they protect bone, another says the drug alone loses more density than exercise alone. The fracture meta-analyses are reassuring and underpowered, and no trial has followed a non-diabetic obesity population long enough to matter.
10 ranked papers · Last verified 2026-08-16
Are GLP-1s Worth What They Cost? 10 Economic Analyses (2026)
Nobody in this literature disputes that the drugs work. What they disagree about is whether the price is defensible, and the answer flips depending on four things: which population, list price or net price, which country, and who paid for the model. This list covers the analyses that coverage decisions are actually argued from.
10 ranked papers · Last verified 2026-08-16

Related Research on Zepbound

Longer pieces written here, built on the trial papers themselves, checked against the FDA label, and argued rather than summarized.

Burping, Reflux and Gas on a GLP-1: The Label's Widest Gap
Eructation runs under 1% on placebo against 7% on Wegovy: a sevenfold difference, and the widest relative gap in the adverse-reactions table. Reflux is a much smaller increase than people expect.
6 min read3 citations
Constipation on a GLP-1: What the Labels Report and What Actually Helps
The Wegovy label reports constipation in 24% against 11% on placebo; the Zepbound label reports it by dose. Here is why it outlasts the nausea, and where the confident advice online runs ahead of the evidence.
6 min read9 citations
GLP-1 Pancreatitis and Gallbladder Risk: What the Labels Counted
Two labeled warnings that are not the same kind of problem. Gallbladder disease tracks with rapid weight loss and is well counted; pancreatitis is rarer, was an exclusion criterion in the pivotal trials, and the database studies disagree.
12 min read19 citations
GLP-1 Hair Loss and Muscle Loss: What Was Measured
Hair shedding and lean-mass loss both appear in the trial record, and both are mostly consequences of losing weight quickly rather than of the drug. That is reassuring about mechanism and not reassuring about outcome, and this holds both.
11 min read15 citations
How Long Do Semaglutide and Tirzepatide Side Effects Last?
What predicts side effects is where you are on the ladder, not how many weeks you have been taking it. Both labels place the nausea and diarrhea during escalation, and how long any single dose keeps working comes down to half-life: roughly seven days for semaglutide, roughly five for tirzepatide.
11 min read8 citations
GLP-1 Telehealth Cancellation and Refund Policies
Can you cancel a GLP-1 telehealth plan any time, and do you get a refund? We read the terms of every seller we track: who lets you stop monthly, who locks you in, and who refunds nothing once medication ships.
6 min read1 citation

Frequently Asked Questions

FDA-approved for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity (November 2023)
What you pay for Zepbound turns on who is selling it and in what form. Uninsured, the branded product runs roughly $1,000 to $1,600 a month; compounded versions through telehealth sellers usually land between $129 and $400. The table above carries the current figures from our register. Before you commit, check whether a manufacturer savings program applies to you.
Common: nausea (31%), diarrhea (23%), vomiting (13%), constipation (12%), abdominal pain (9%), injection site redness. Nausea is most common during dose escalation and typically resolves within a month of each new dose. Serious (rare): pancreatitis, cholelithiasis (gallstones), thyroid tumor risk noted in animal models. The suicidal behavior and ideation section was removed from the label in February 2026.
Zepbound is prescription-only, so someone licensed has to write it — your own doctor, an endocrinologist, or one of the telehealth sellers above. For compounded versions the telehealth route is usually both quicker and cheaper out of pocket than a traditional pharmacy.
Sources & methodology — as of September 2026
  1. 1.FDA — Zepbound (tirzepatide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
  2. 2.SURMOUNT-1 Trial — Tirzepatide Once Weekly for the Treatment of Obesity (Jastreboff AM et al.)— New England Journal of Medicine.PMID: 35658024.
  3. 3.SURMOUNT-5 Trial — Tirzepatide vs. Semaglutide Head-to-Head in Obesity (Garvey WT et al.)— New England Journal of Medicine.PMID: 40334173.
  4. 4.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
  5. 5.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
  6. 6.IRS Publication 502 — Medical and Dental Expenses (HSA/FSA eligibility)— Internal Revenue Service.

Glossary

The words sellers use, defined. Tap any term.